Fred Grossman D.O., FAPA

Fred Grossman D.O., FAPA has over 25 years of experience in the pharmaceutical and biotechnology industries. Their most recent role is President and Chief Medical Officer at Coya Therapeutics, Inc since July 2023. Prior to that, they served as an Independent Board Director at Reunion Neuroscience starting in April 2023. At Empyrean Neuroscience, they held the position of Chief Medical Officer and Head of Translational Medicine from February 2022 to February 2023.

Between 2019 and 2022, Dr. Grossman served as Chief Medical Officer at Mesoblast Limited, where they played a critical role in the development of allogeneic cellular medications. Fred was responsible for the clinical development of several late-stage product candidates.

From 2018 to 2019, they held the position of Chief Medical Officer at NeuroRx Pharma, a clinical-stage pharmaceutical company specializing in central nervous system disorders.

Dr. Grossman's career also includes significant roles at Glenmark Pharmaceuticals, Sunovion Pharmaceuticals, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly, where they held various leadership positions in medical affairs, clinical development, and global strategy.

Throughout their career, Dr. Grossman has demonstrated expertise in strategic planning, clinical development, medical affairs, and regulatory negotiations. Fred has made valuable contributions to the advancement of innovative therapies in multiple therapeutic areas, including neurology, psychiatry, oncology, immunology, and virology. Dr. Grossman is a highly respected medical professional with a deep understanding of the industry and a track record of success.

Fred Grossman D.O., FAPA completed their education in the field of Psychiatry and Geriatric Psychiatry. From 1986 to 1991, they attended Hahnemann University and the National Institutes of Health, where they pursued a Psychiatry Residency and a Pharmacology Fellowship.